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PP-162 Markers of adipocytokine and endothelial injury
in antiretroviral-naive HIV patients
L. Li1 *, J. Chen1, H.Z. Lu1,2, L. Liu1, R.F. Zhang1,
Y.F. Zheng1. 1Department of Infectious Disease, Shanghai
Public Health Clinical Center afﬁliated to Fudan University,
2Department of Infectious Disease, HuaShan Hospital
afﬁliated to Fudan University, China
Background: Untreated human immunodeﬁciency virus
(HIV) infection is associated with increased risk for
cardiovascular disease. Current data are limited and
contradictory. Our aim is to investigate the markers of
adipocytokine, endothelial injury and thrombotic activity
and explore whether there are cardiovascular disease risk
factors in antiretroviral-naive HIV patients.
Methods: Clinical data and venous blood samples were
collected from 43 ARV naı¨ve AIDS patients during
February October 2009 in our center, and compared with
17 healthy subjects. Plasma leptin, adiponectin, soluble
intercellular adhesion molecule-1 (sICAM-1), D-dimer
were measured by enzyme-linked immunosorbent assay
(ELISA). 4 markers and cholesterol, triglyceride, fasting
plasma glucose were compared between the 2 groups.
Spearman correlations between the signiﬁcant markers and
CD4+ T cells, CD8+CD38+/CD8+ %, CD8+HLA-DR+/CD8+ %,
HIV viral load were examined among HIV-infected
participants. Analyses were conducted by using Stata
version 7.
Results: 88.37% of the 43 patients were sexually infected
by HIV and the mean CD4+T count was (133±82)
cells/mL, HIV RNA was (4.42±0.66)log copies/mL. HIV-
infected participants, compared with healthy subjects,
had lower leptin, adiponectin (P= 0.0005, P= 0.0030) and
higher sICAM-1 (P= 0.0000). No signiﬁcant differences exist
in cholesterol, triglyceride, fasting plasma glucose. For HIV-
infected participants, sICAM-1 tended to correlate with
CD8+CD38+/CD8+% and HIV viral load (r = 0.3389, P= 0.0374;
r = 0.4512, P= 0.0182).
Conclusion:Persons with untreated HIV infection have
lower leptin, adiponectin and higher sICAM-1 levels
and the relationship of these markers to HIV-mediated
atherosclerotic risk requires further study.
PP-163 No impact of TangHerb on the efavirenz plasma
concentration among HIV-infected patients
in China
J. Chen1 *, H.Z. Lu1, L.J. Zhang1, Y.M. Yao1. 1Shanghai
Public Health Clinical Center, China
Background: The use of traditional Chinese medicine is
widespread in China, even among HIV-infected patients.
However, the potential drug interaction has not been
well studied. We evaluate the impact of TangHerb (a
proprietary Chinese medicine for AIDS treatment) on the
efavirenz plasma concentration and the safety and efﬁcacy
of efavirenz when be used in combined with TangHerb.
Methods: Fifty HIV-infected patients taking efavirenz
containing antiretroviral regimens were enrolled. Twenty
of them were taking TangHerb (eight capsules 3 times per
day) together while 30 of them were not. Steady-state
plasma concentrations of efavirenz were determined using
HPLC-MS detection. Efavirenz associated central nervous
system side effects and the frequency of viralogic failure
was observed.
Results: No signiﬁcant difference of the efavirenz
concentration between these two groups was found
(2765 ng/ml vs 2325 ng/ml, P = 0.25). No factors including
age, gender, body mass index, alanine transaminase
and CD4 cell count were associated with efavirenz
concentration in multi-regression analysis. The frequency
of efavirenz associated central nervous system side effects
and viralogic failure were also comparable among these two
populations.
Conclusion: TangHerb does not impact the EFV steady
plasma concentration and its efﬁcacy. It could be used
safely together with EFV.
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PP-164 The clinical features of ocular manifestations in
HIV/AIDS
J. Xiao1, H.-Y. He2, N. Han1, L.-H. Wang1, G.-J. Gao1,
L. Liu1, D. Yang1, L.-Y. Zhang1, H.-X. Zhao1 *. 1Division 1
of Department of Infectious Diseases, 2Department of
Ophthalmology, Beijing, China
Objective: To promote the diagnostic rate of ocular diseases
complicated with HIV/AIDS, understand clinical features of
HIV-associated ocular diseases, enhance curative effects
and improve the prognosis.
Patients and Methods: The clinical data and ophthalmic
records in 92 cases of HIV/AIDS patients hospitalized
from October 2008 to February 2010 have been collected
retrospectively; and we focus on clinical features, ocular
manifestations, ophthalmic examination, CD4 counts and
opportunistic infections, in which ocular manifestations and
CD4 counts were analyzed statistically with c2 test.
Results: We found that prevalence of retinopathy, most
common HIV-associated ocular disease, was 34.8%; the
